Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder
| Autor: | Kristina A Ryzhikova, Michael S. Zastrozhin, Inessa A. Bedina, Egor Chumakov, Dmitry A. Sychev, Anastasiya Petrovna, Evgeny A Brun, Alexander S. Sorokin, Valentin Yurievich Skryabin, Ludmila M. Savchenko, Oleg Z. Buzik, Marco Torrado, Elena A. Grishina |
|---|---|
| Přispěvatelé: | Repositório da Universidade de Lisboa |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Alcohol addiction CYP2C19 Alcohol use disorder 030226 pharmacology & pharmacy 03 medical and health sciences Benzodiazepines 0302 clinical medicine Rating scale Internal medicine Genetics medicine Genotyping Biotransformation Pharmacology business.industry Alcohol dependence Phenazepam Bromodihydrochlorobenzodiazepine medicine.disease Personalized medicine 030220 oncology & carcinogenesis Molecular Medicine Anxiety medicine.symptom business Anxiety disorder medicine.drug Anxiety disorders |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP |
| Popis: | © 2020 Future Science Group. Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2. This work was supported by the project titled “Fundamental research and exploratory research in priority areas of research” of the Russian Science Foundation and by the President’s Grant of state support for the young scientists (project MK-2460.2018.7). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|